Although neuroendocrine cancer is an umbrella term for a group of individually rare cancers, it is less rare than official ...
Peripheral primitive neuroectodermal tumors (pPNETs) are small embryonic carcinomas that develop in the soft tissue and bone, away from the central nervous system (CNS) and sympathetic nervous system ...
The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...
Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results